Thrombocytosis: Difference between revisions

Line 10: Line 10:
*Vasomotor symptoms are due to microvascular disturbances and include: headache, lightheadedness, syncope, acral paresthesia, atypical chest pain, livedo reticularis, erythromelalgia, and transient visual disturbances. <ref>Tefferi, "Diagnosis and Clinical Manifestations of Essential Thrombocythemia," UpToDate, Jul. 2017.</ref>
*Vasomotor symptoms are due to microvascular disturbances and include: headache, lightheadedness, syncope, acral paresthesia, atypical chest pain, livedo reticularis, erythromelalgia, and transient visual disturbances. <ref>Tefferi, "Diagnosis and Clinical Manifestations of Essential Thrombocythemia," UpToDate, Jul. 2017.</ref>


==Differential Diagnosis==
==Differential Diagnosis<ref>Tefferi, "Diagnosis and Clinical Manifestations of Essential Thrombocythemia," UpToDate, Jul. 2017.</ref>==
*Reactive thrombocytosis:
===Reactive thrombocytosis===
** Acute blood loss
* Acute blood loss
** Acute hemolytic anemia
* Acute hemolytic anemia
** Iron deficiency anemia
* Iron deficiency anemia
** Treatment of vitamin B12 deficiency
* Treatment of [[vitamin B12 deficiency]]
**Rebound effect after thrombocytopenia treatment
*Rebound effect after thrombocytopenia treatment
** Metastatic cancer
* Metastatic cancer
** Lymphoma
* [[Lymphoma]]
** Rheumatologic disorders
* Rheumatologic disorders
** IBD
* [[IBD]]
** Celiac disease
* Celiac disease
** Kawasaki disease
* [[Kawasaki disease]]
** Nephrotic syndrome
* [[Nephrotic syndrome]]
** POEMS syndrome
* POEMS syndrome
** Thermal burn
* Thermal [[burn]]
** MI
* [[MI ]]
** Severe trauma
* Severe trauma
** Acute pancreatitis
* [[Acute pancreatitis]]
** Post-surgery, especially splenectomy
* Post-surgery, especially splenectomy
** CABG
* CABG
** TB
* [[TB]]
** Acute bacterial/viral infections
* Acute bacterial/viral infections
** Asplenia
* Asplenia
** Allergic reactions
* [[Allergic reaction]]
** Medication reactions: vincristine, epinephrine, glucocorticoids, IL-1B, ATRA, thrombopoietin, LMWH  (uptodate)
* Medication reactions: vincristine, epinephrine, glucocorticoids, IL-1B, ATRA, thrombopoietin, LMWH  (uptodate)
*Autonomous thrombocytosis:
 
** Essential Thrombocytopenia
===Autonomous thrombocytosis===
** Polycythemia Vera
* Essential thrombocytopenia
** Mixed myelodysplastic and/or myeloproliferative syndrome
* [[Polycythemia vera]]
*Spurious (false) thrombocytosis:
* Mixed myelodysplastic and/or myeloproliferative syndrome
** Mixed cryoglobulinemia
 
** Cytoplasmic fragments
===Spurious (false) thrombocytosis===
** Bacteremia<ref>Tefferi, "Diagnosis and Clinical Manifestations of Essential Thrombocythemia," UpToDate, Jul. 2017.</ref>
* Mixed cryoglobulinemia
* Cytoplasmic fragments
* [[Bacteremia]]


==Evaluation==
==Evaluation==

Revision as of 12:09, 19 September 2017

Background

  • Defined as a platelet count >450,000/microL.
  • Can be reactive or autonomous.
    • Reactive thrombocytosis (RT) is the most common cause of thrombocytosis, accounting for 85% of cases. RT is a reaction to another process, such as inflammation, infection, cancer, or iron deficiency. RT rarely causes complications even with extremely elevated platelet counts (>1,000,000/microL).
    • Autonomous thrombocytosis (AT) accounts for 15% of cases. AT is a primary problem that results from myeloproliferative disorders or myelodysplastic disorders, such as essential thrombocytopenia or polycythemia vera. Complications, such as bleeding and/or thrombosis, are more likely with AT than with RT so it is clinically important to differentiate reactive thrombocytosis versus autonomous thrombocytosis. There are no diagnostic studies to differentiate RT versus AT. [1]

Clinical Features

  • Generally asymptomatic and found on routine lab testing.
  • Complications are seen in AT disorders and include thrombosis, bleeding, or vasomotor symptoms. Thrombotic complications are the leading cause of morbidity and mortality. Thrombosis commonly occurs in arteries (stroke, TIA, MI, unstable angina), but can also occur in the venous system (DVT, PE, Budd-Chiari syndrome). Serious bleeding is a less common complication and is generally seen in the nasal and bucchal mucosa and the GI tract.
  • Vasomotor symptoms are due to microvascular disturbances and include: headache, lightheadedness, syncope, acral paresthesia, atypical chest pain, livedo reticularis, erythromelalgia, and transient visual disturbances. [2]

Differential Diagnosis[3]

Reactive thrombocytosis

Autonomous thrombocytosis

  • Essential thrombocytopenia
  • Polycythemia vera
  • Mixed myelodysplastic and/or myeloproliferative syndrome

Spurious (false) thrombocytosis

  • Mixed cryoglobulinemia
  • Cytoplasmic fragments
  • Bacteremia

Evaluation

Workup

  • Labs
    • CBC, ESR, CRP, iron studies, LDH
  • CXR
  • Fecal occult blood test

Diagnosis

  • platelet count >450,000/microL.

Management

Reactive thrombocytosis

  • Treat underlying disease.

Autonomous thrombocytosis

Asymptomatic

  • 81mg ASA PO daily.
  • If high risk for thrombotic event (>60 yrs, history of thrombosis, or known JAK2 mutation), consider 15mg/kg hydroxyurea PO daily. Consult if available.
  • Second line agents include IFN-alpha, anagrelide, and pipobroman.

Thrombosis due to AT

  • Anticoagulation with LMWH.
  • 81mg ASA PO daily.
  • Consult heme/onc
  • Consider 3-5 million U IFN alpha SQ daily if <40 years old. 15mg/kg hydroxyurea PO daily if >40 years old. Goal platelet count <400,000/microL.
  • Platelet apheresis if platelet count >800,000/microL.

Bleeding due to AT

  • Discontinue antiplatelet medications.
  • Consult.
  • Consider 3-5 million U IFN alpha SQ daily if <40 years old. 15mg/kg hydroxyurea PO daily if >40 years old. Goal platelet count <400,000/microL.[4]

Disposition

Reactive thrombocytosis

  • Disposition is based on underlying disorder.

Autonomous thrombocytosis

  • If asymptomatic, consider outpatient treatment with close follow up.
  • If thrombosis or bleeding complications, should be admitted for stabilization and further work up.

External Links

References

  1. Schafer, "Thrombocytosis," N Engl J Med 2004;350:1211-9.
  2. Tefferi, "Diagnosis and Clinical Manifestations of Essential Thrombocythemia," UpToDate, Jul. 2017.
  3. Tefferi, "Diagnosis and Clinical Manifestations of Essential Thrombocythemia," UpToDate, Jul. 2017.
  4. Bleeker, "Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies," Thrombosis. 2011; 2011: 536062. Published online 2011 Jun 8. doi:10.1155/2011/536062.